These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 32238005)
41. [Clinical Approach to Individualization of Antimicrobial Therapy Based on Pharmacokinetic/Pharmacodynamic Analysis and Therapeutic Drug Monitoring]. Sato Y; Suzuki Y; Tanaka R; Kaneko T; Itoh H Yakugaku Zasshi; 2019; 139(6):917-922. PubMed ID: 31155536 [TBL] [Abstract][Full Text] [Related]
42. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). Hall RG; Thatcher M; Wei W; Varghese S; Varughese L; Ndiulor M; Payne KD Expert Rev Clin Pharmacol; 2017 May; 10(5):493-508. PubMed ID: 28293964 [TBL] [Abstract][Full Text] [Related]
43. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Blot SI; Pea F; Lipman J Adv Drug Deliv Rev; 2014 Nov; 77():3-11. PubMed ID: 25038549 [TBL] [Abstract][Full Text] [Related]
44. [Optimization of antimicrobial therapy based on therapeutic drug monitoring]. Morita K Yakugaku Zasshi; 2011; 131(10):1407-13. PubMed ID: 21963966 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents in Burn Patients. Pruskowski KA Surg Infect (Larchmt); 2021 Feb; 22(1):77-82. PubMed ID: 33164665 [No Abstract] [Full Text] [Related]
46. [Personalised antibiotic therapy in a surgical intensive care unit overview of current knowledge and the results of an observational kinetic study]. Kaška M; Martinková J; Havel E; Kočí J; Fousková A; Solichová D; Kujovská L; Selke-Krulichová I; Práznovec I; Salavec V Rozhl Chir; 2014 Sep; 93(9):456-62. PubMed ID: 25301344 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic issues for antibiotics in the critically ill patient. Roberts JA; Lipman J Crit Care Med; 2009 Mar; 37(3):840-51; quiz 859. PubMed ID: 19237886 [TBL] [Abstract][Full Text] [Related]
48. Optimising β -lactam Dosing in Neonates: A Review of Pharmacokinetics, Drug Exposure and Pathogens. Fuchs A; Li G; van den Anker JN; Bielicki J Curr Pharm Des; 2017; 23(38):5805-5838. PubMed ID: 28950814 [TBL] [Abstract][Full Text] [Related]
49. Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections. Pea F Curr Opin Infect Dis; 2016 Apr; 29(2):153-9. PubMed ID: 26836376 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit. Williams P; Cotta MO; Roberts JA Semin Respir Crit Care Med; 2019 Aug; 40(4):476-487. PubMed ID: 31585474 [TBL] [Abstract][Full Text] [Related]
51. Personalised antimicrobial dosing: standing on the shoulders of giants. Wallenburg E; Ter Heine R; Schouten JA; Brüggemann RJM Int J Antimicrob Agents; 2020 Sep; 56(3):106062. PubMed ID: 32574792 [TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. De Paepe P; Belpaire FM; Buylaert WA Clin Pharmacokinet; 2002; 41(14):1135-51. PubMed ID: 12405864 [TBL] [Abstract][Full Text] [Related]
53. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. John J; Loo A; Mazur S; Walsh TJ Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):881-895. PubMed ID: 31550939 [No Abstract] [Full Text] [Related]
54. Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review. Rashed AN; Jackson C; Gastine S; Hsia Y; Bielicki J; Standing JF; Tomlin S; Sharland M Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1099-1106. PubMed ID: 31760892 [No Abstract] [Full Text] [Related]
55. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974 [TBL] [Abstract][Full Text] [Related]
56. A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy. Pistolesi V; Morabito S; Di Mario F; Regolisti G; Cantarelli C; Fiaccadori E Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109983 [TBL] [Abstract][Full Text] [Related]
57. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443 [TBL] [Abstract][Full Text] [Related]
58. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Perrott J; Mabasa VH; Ensom MH Ann Pharmacother; 2010 Mar; 44(3):557-64. PubMed ID: 20124468 [TBL] [Abstract][Full Text] [Related]